Acute Kidney Injury
Pipeline by Development Stage
Drug Modality Breakdown
Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.
Key Trends
- GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
- Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
- Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research
Career Verdict
Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 25% | Peak | Stable | 12.4yr |
| 2 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 24% | Peak | Stable | 8.6yr |
| 3 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 20% | Peak | Stable | |
| 4 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 12% | Peak | Stable | 15.4yr |
Drug Class Breakdown
cardiometabolic dominance
cardioprotective expansion
heart failure crossover
overactive bladder niche
declining relevance
Career Outlook
StableNephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.
Breaking In
Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.
For Experienced Professionals
Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.
In-Demand Skills
Best For
Hiring Landscape
Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.
Top Hiring Companies
By Department
Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.
Competitive Landscape
34 companies ranked by most advanced pipeline stage
+4 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 45 trials with date data
Clinical Trials (45)
Total enrollment: 657,278 patients across 45 trials
Albumin To Enhance Recovery After Acute Kidney Injury
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
Levosimendan in Acute Kidney Injury Study
Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
A Phase I Study to Evaluate LSALT Peptide
RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD
Hamburg Acute Renal Injury Study (HARIS)
Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis
Characteristics of Renal Blood Flow in AKI Patients in ICU and Its Clinical Significance
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
Aortix Therapy for Perioperative Reduction of Kidney Injury
Improving Continuous Renal Replacement Therapy Outcomes in Neonates and Infants Through Interdisciplinary Collaboration
RRT With a Cytokine Absorption Filter (oXiris ®) in Patients With Septic Shock
Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.
Evaluation of Renal Damage After PCNL and ESWL Using Novel RNA Based Biomarkers
Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
Macro and Micro Haemodynamic Responses to Shock in the Renal and Systemic - MICROSHOCK - RENAL
Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury
Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study
Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
European Registry of Dialysis Treatment of Pediatric Acute Kidney Injury (AKI)
Renal Safety of Bowel Preparation With Polyethylene Glycol
Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)
Diagnostic Value of Urinary Indices in Differentiating Pre-renal and Renal Acute Kidney Injury
Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU
Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)
Long-term Survival and Renal Outcomes in Critically Ill Patients After Acute Kidney Injury: Swedish Multi-centre Cohort Study
Related Jobs in Nephrology
Project Manager, On-Market Products - Pleasanton, CA
Staff Systems Engineer - Pleasanton, CA
Area Sales Manager (Georgia)
Farm Operations Technician
Sr. Research and Development Technician - Pleasanton, CA
Chicago South based Clinical Specialist - Remote, USA
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.